NAD+ Biology: The Central Molecule of Longevity Science

By AXEL Science Team 9 min read

The NAD+ Decline Problem

Nicotinamide adenine dinucleotide (NAD+) is arguably the most important coenzyme in the body — involved in over 500 enzymatic reactions, it is essential for ATP production, DNA repair, circadian rhythm regulation, and the activation of sirtuins (the 'longevity proteins'). The problem: NAD+ levels decline by approximately 50% between ages 40 and 60 (Yoshino et al., 2018, Cell Metabolism).

This decline accelerates every major hallmark of aging: mitochondrial dysfunction, genomic instability, impaired autophagy, and dysregulated senescence.

The Sirtuin Connection

Sirtuins (SIRT1–7) are NAD+-dependent deacetylases that regulate gene expression, metabolic homeostasis, and cellular stress responses. Without sufficient NAD+, sirtuin activity collapses — and with it, the cell's ability to repair DNA, regulate inflammation, and maintain metabolic efficiency. David Sinclair's laboratory at Harvard has extensively documented this relationship, establishing NAD+ repletion as a cornerstone of aging intervention.

NMN vs NR: What the Evidence Says

Nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) are the two primary NAD+ precursors studied in humans. Yoshino et al. (2021, Science) published the first randomized, placebo-controlled trial of NMN in postmenopausal women with prediabetes, demonstrating significant improvements in skeletal muscle insulin sensitivity and NAD+ metabolomics without adverse effects.

NR clinical data from Elhassan et al. (2019, Cell Reports Medicine) confirmed oral NR supplementation at 1g/day increased blood NAD+ levels by 2.7-fold in healthy elderly subjects. Muscle NAD+ metabolites and mitochondrial gene expression were also elevated.

Integration with Longevity Protocols

At AXEL, NAD+ precursor therapy is always assessed in the context of a full terrain biomarker panel. Baseline whole-blood NAD+ measurement guides protocol dosing, and follow-up testing at 8–12 weeks confirms clinical response. NAD+ therapy does not exist in isolation — it functions synergistically with CoQ10, liposomal glutathione, and sirtuinactivating compounds (STACs) such as resveratrol and pterostilbene.